Jose A Rodriguez

List of Publications by Year
in descending order

73	2,316	159358	233125
papers	citations	30 h-index	45 g-index

87	87	87	3524
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CM-352 EFFICACY IN A MOUSE MODEL OF ANTICOAGULANT-ASSOCIATED INTRACRANIAL HAEMORRHAGE. Thrombosis and Haemostasis, 2022, 0, .	1.8	0
2	Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery, 2022, 63, 648-656.	0.8	8
3	Matrix Metalloproteinase 10 Contributes to Choroidal Neovascularisation. Biomedicines, 2022, 10, 1557.	1.4	1
4	Association of SDF1 and MMP12 with Atherosclerosis and Inflammation: Clinical and Experimental Study. Life, 2021, 11, 414.	1.1	9
5	Inner ear drug delivery through a cochlear implant: Pharmacokinetics in a Macaque experimental model. Hearing Research, 2021, 404, 108228.	0.9	18
6	The Bone Regeneration Capacity of BMP-2 + MMP-10 Loaded Scaffolds Depends on the Tissue Status. Pharmaceutics, 2021, 13, 979.	2.0	3
7	Molecular and Cellular Mechanisms of Delayed Fracture Healing in Mmp10 (Stromelysin 2) Knockout Mice. Journal of Bone and Mineral Research, 2021, 36, 2203-2213.	3.1	5
8	MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade. Scientific Reports, 2020, 10, 26.	1.6	24
9	A Role for MMP-10 (Matrix Metalloproteinase-10) in Calcific Aortic Valve Stenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1370-1382.	1.1	36
10	Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. Scientific Reports, 2020, 10, 10329.	1.6	5
11	Elevated circulating metalloproteinase 7 predicts recurrent cardiovascular events in patients with carotid stenosis: a prospective cohort study. BMC Cardiovascular Disorders, 2020, 20, 93.	0.7	5
12	Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD). Journal of Extracellular Vesicles, 2020, 9, 1729646.	5.5	34
13	MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes. Translational Stroke Research, 2019, 10, 389-401.	2.3	21
14	High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients. BMC Neurology, 2019, 19, 167.	0.8	6
15	Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease. Scientific Reports, 2019, 9, 15580.	1.6	91
16	Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients. Journal of Critical Care, 2019, 51, 117-121.	1.0	5
17	AnÃ¡lisis de subpoblaciones monocitarias en relaciÃ³n con los factores de riesgo cardiovascular. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2019, 31, 152-159.	0.4	1
18	Combined sustained release of BMP2 and MMP10 accelerates bone formation and mineralization of calvaria critical size defect in mice. Drug Delivery, 2018, 25, 750-756.	2.5	25

#	Article	IF	Citations
19	Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. ACS Medicinal Chemistry Letters, 2018, 9, 428-433.	1.3	2
20	Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification. Atherosclerosis, 2018, 278, 124-134.	0.4	27
21	Selective increase of cardiomyocyte derived extracellular vesicles after experimental myocardial infarction and functional effects on the endothelium. Thrombosis Research, 2018, 170, 1-9.	0.8	12
22	CM352 Reduces Brain Damage and Improves Functional Recovery in a Rat Model of Intracerebral Hemorrhage. Journal of the American Heart Association, 2017, 6, .	1.6	24
23	New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. Cardiovascular Research, 2017, 113, 1219-1229.	1.8	15
24	Reduced high-density lipoprotein cholesterol: A valuable, independent prognostic marker in peripheral arterial disease. Journal of Vascular Surgery, 2017, 66, 1527-1533.e1.	0.6	19
25	Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors. DMM Disease Models and Mechanisms, 2016, 9, 541-52.	1.2	42
26	Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/Câ€Xâ€C chemokine receptor 4 axis. Hepatology, 2015, 62, 166-178.	3.6	61
27	Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease. Journal of Vascular Surgery, 2015, 61, 428-435.	0.6	35
28	Discovery and Safety Profiling of a Potent Preclinical Candidate, (4-[4-[[(3R)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the Prevention and Treatment of Hemorrhage. Journal of Medicinal Chemistry, 2015, 58, 2941-2957.	2.9	11
29	Design, Synthesis, and Biological Evaluation of Novel Matrix Metalloproteinase Inhibitors As Potent Antihemorrhagic Agents: From Hit Identification to an Optimized Lead. Journal of Medicinal Chemistry, 2015, 58, 2465-2488.	2.9	18
30	Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke. Thrombosis Research, 2015, 136, 445-450.	0.8	15
31	Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction. BMC Neurology, 2015, 15, 111.	0.8	11
32	Functional MMPâ€10 is required for efficient tissue repair after experimental hind limb ischemia. FASEB Journal, 2015, 29, 960-972.	0.2	19
33	Association of Sepsis-Related Mortality with Early Increase of TIMP-1/MMP-9 Ratio. PLoS ONE, 2014, 9, e94318.	1.1	60
34	Association between Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and Mortality in Patients with Severe Brain Trauma Injury. PLoS ONE, 2014, 9, e94370.	1.1	34
35	The CXCR4/SDF1 Axis Improves Muscle Regeneration Through MMP-10 Activity. Stem Cells and Development, 2014, 23, 1417-1427.	1.1	36
36	MMP-10 Is Required for Efficient Muscle Regeneration in Mouse Models of Injury and Muscular Dystrophy. Stem Cells, 2014, 32, 447-461.	1.4	39

#	Article	IF	Citations
37	Matrix metalloproteinaseâ€10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair. Liver International, 2014, 34, e257-70.	1.9	43
38	C0288: Lack of TAFI Has Deleterious Effect on Experimental Ischemic Stroke: Potential Role of Microparticles. Thrombosis Research, 2014, 133, S5.	0.8	1
39	The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. Critical Care, 2013, 17, R94.	2.5	31
40	300 IDENTIFICATION OF MATRIX METALLOPROTEASE 10 (MMP10) AS A KEY NEW MEDIATOR OF THE REGENERATIVE RESPONSE OF THE LIVER. Journal of Hepatology, 2013, 58, S126.	1.8	0
41	Effect of Lutein and Antioxidant Supplementation on VEGF Expression, MMP-2 Activity, and Ultrastructural Alterations in Apolipoprotein E-Deficient Mouse. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-11.	1.9	25
42	Synergistic Effect of Thrombin and CD40 Ligand on Endothelial Matrix Metalloproteinase-10 Expression and Microparticle Generation In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1477-1487.	1.1	53
43	Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Critical Care, 2011, 15, R97.	2.5	53
44	Matrix Metalloproteinase-10 Effectively Reduces Infarct Size in Experimental Stroke by Enhancing Fibrinolysis via a Thrombin-Activatable Fibrinolysis Inhibitorâ€"Mediated Mechanism. Circulation, 2011, 124, 2909-2919.	1.6	54
45	W43 GENETIC DEFICIENCY IN FUNCTIONAL MMP-10 REDUCES PROGRESSION OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-KNOCKOUT MICE. Atherosclerosis Supplements, 2010, 11, 9-10.	1.2	0
46	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 78, 1275-1280.	2.6	37
47	Matrix Metalloproteinase-10 Is Upregulated by Thrombin in Endothelial Cells and Increased in Patients With Enhanced Thrombin Generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2109-2116.	1.1	42
48	Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Critical Care, 2009, 13, R158.	2.5	105
49	Stromelysin-2 (MMP-10) deficiency does not affect adipose tissue formation in a mouse model of nutritionally induced obesity. Biochemical and Biophysical Research Communications, 2009, 389, 378-381.	1.0	24
50	Egg yolk improves lipid profile, lipid peroxidation and retinal abnormalities in a murine model of genetic hypercholesterolemia. Journal of Nutritional Biochemistry, 2008, 19, 40-48.	1.9	23
51	Respuesta. Revista Espanola De Cardiologia, 2008, 61, 327-328.	0.6	5
52	Association Between Matrix Metalloproteinase-10 Concentration and Smoking in Individuals Without Cardiovascular Disease. Revista Espanola De Cardiologia (English Ed), 2008, 61, 1267-1273.	0.4	6
53	Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thrombosis and Haemostasis, 2008, 99, 382-387.	1.8	59
54	Antioxidant effects of vitamins C and E, multivitamin-mineral complex and flavonoids in a model of retinal oxidative stress: The ApoE-deficient mouse. Experimental Eye Research, 2008, 86, 470-479.	1.2	16

#	Article	IF	Citations
55	Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Frontiers in Bioscience - Landmark, 2008, 13, 2916.	3.0	78
56	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 587-593.	1.1	82
57	PO9-266 VASCULAR MATRIX METALLOPROTEINASE 10 (MMP-10) EXPRESSION IS ASSOCIATED WITH INFLAMMATION AND ATHEROSCLEROSIS DEVELOPMENT IN A MURINE MODEL. Atherosclerosis Supplements, 2007, 8, 83.	1.2	0
58	Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. Journal of Thrombosis and Haemostasis, 2007, 5, 91-97.	1.9	62
59	Th-W56:5 MMP-10 (stromelysin-2): New biomarker for clinical and subclinical atherosclerosis. Atherosclerosis Supplements, 2006, 7, 480.	1.2	0
60	C-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells. Journal of the American College of Cardiology, 2006, 47, 1369-1378.	1.2	168
61	Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clinica Chimica Acta, 2006, 368, 138-143.	0.5	52
62	Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL. Cardiovascular Research, 2005, 65, 665-673.	1.8	44
63	Vitamins C and E Reduce Retinal Oxidative Stress and Nitric Oxide Metabolites and Prevent Ultrastructural Alterations in Porcine Hypercholesterolemia. , 2005, 46, 1140.		45
64	W03-O-003 Effect of folic acid and vitamin B12 on endothelial function, oxidative stress and prothrombotic factors after renal transplantation. Atherosclerosis Supplements, 2005, 6, 12.	1.2	0
65	W12-P-042 C-reactive protein mediates MMP-1 and MMP-10 expression in human endothelial cells and in patients with atherosclerosis. Atherosclerosis Supplements, 2005, 6, 72.	1.2	0
66	Effects of cryopreservation on the immunogenicity of porcine arterial allografts in early stages of transplant vasculopathy. Cryobiology, 2005, 51, 130-141.	0.3	20
67	Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovascular Research, 2004, 63, 176-185.	1.8	17
68	Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stabilization. Atherosclerosis, 2003, 167, 45-53.	0.4	61
69	Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. Atherosclerosis, 2003, 171, 67-73.	0.4	64
70	Dietary supplementation with vitamins C and E prevents downregulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro. Atherosclerosis, 2002, 165, 33-40.	0.4	44
71	Hyperhomocysteinemia in Liver Cirrhosis. Hypertension, 2001, 38, 1217-1221.	1.3	97
72	Torasemide Inhibits Angiotensin IIâ€“Induced Vasoconstriction and Intracellular Calcium Increase in the Aorta of Spontaneously Hypertensive Rats. Hypertension, 1999, 34, 138-143.	1.3	48

#	Article	IF	Citations
73	Role of Programmed Electrical Stimulation of the Heart in Risk Stratification Post-Myocardial Infarction. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 283-288.	0.5	6